Harnessing the power of Artificial Intelligence to unlock further potential of known drugs for orphan diseases

We leverage the power of Artificial Intelligence to repurpose drugs for orphan diseases

We are a team of talented scientists with a passion for innovation

Learn about us

STANDARD DRUG DISCOVERY AND DEVELOPMENT

WE CAN REDUCE THOSE NUMBERS TO

OUR APPROACH

PROPRIETARY PIPELINE

PARTNERSHIP

OUR PERFORMANCE INDICATORS

WE COOPERATE WITH

SOM BIOTECH IN THE MEDIA

LATEST NEWS

The Brazilian Journal of Implantology and Health Sciences cites SOM3355 as a promising therapy for chorea in Huntington’s disease.

June 19, 2024
The current issue of The Brazilian Journal of Implantology and Health Sciences (Volume 6, Issue 6 (2024), Page 1040-105) cites SOM3355 as a promising therapy for chorea in Huntington’s disease.

SOM Biotech appoints George G. Montgomery as Strategic Corporate Advisor

May 28, 2024
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent platform, has appointed George G. Montgomery as Strategic Corporate Advisor to the Board.

SOM Biotech announces the completion of recruitment in the Phase IIb study of the treatment of chorea in Huntington’s disease patients with SOM3355

April 10, 2024
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has been completed.

SOM Biotech announces the election of Silvia Panigone as Executive Chair

March 27, 2024
Barcelona, Spain, March 26th, 2024. SOM Biotech (SOM), a clinical-stage drug discovery and development company based on a unique and proprietary Artificial Intelligent (AI) platform, appoints Silvia Panigone PhD, MBA as Executive Chair of the Board of SOM.

SOM Biotech closes an internal round for €5.5 Million

March 13, 2024
Barcelona, Spain. March 12, 2024. SOM Biotech (“SOM” or the “Company”), a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent (AI) platform, announces the closure of an internal round for € 5.5 million to secure the completion of the Phase IIb study on Huntington patients with its lead candidate SOM3355.…

SOM Biotech at the 10th Drug Discovery Innovation Programme

November 29, 2019
SOM Biotech participated in the 10th Drug Discovery Innovation Programme that took place on November 28th -29th- in Barcelona, Spain. Luca Signorile – Computational Chemist of SOM Biotech –performed the presentation on the topic “Re-Discovering Drugs: Advantages, Perspectives, and the role of AI.” During his speech, he gave an insight into the computational side of…